1
Executive Summary
Comprehensive documentation of PDMP reviews and UDS ordering is not merely administrative overhead—it is a critical component of safe controlled substance prescribing. This guide provides evidence-based protocols for psychiatric mental health nurse practitioners.
Why This Matters
Proper documentation protects patients, satisfies legal requirements, establishes standard of care compliance, and provides malpractice protection through evidence of due diligence.
50+
States with PDMP Mandates
4x
Overdose Risk with Concurrent Benzo/Opioid
30%
Of UDS Show Unexpected Results
100%
DEA Audit Survival with Documentation
2
Why We Document PDMP/UDS
- Legal Requirement: Most states mandate PDMP checks before prescribing Schedule II-IV controlled substances. Failure to check can result in board action.
- Standard of Care: Even in non-mandate states, failure to check the PDMP before prescribing constitutes a deviation from standard of care and creates significant liability exposure.
- Patient Safety: PDMP reviews identify multiple prescribers, detect potential diversion, and reveal unreported substances that could interact with prescribed medications.
- Malpractice Protection: Documented PDMP checks serve as evidence of due diligence in the event of adverse outcomes or board complaints.
- Insurance/DEA Compliance: Audited practices must demonstrate PDMP compliance through documentation. Insurance carriers may require PDMP reviews for continued coverage.
3
PDMP Check Requirements
| When to Check | Requirement Level | Rationale |
|---|---|---|
| New controlled substance prescription | Mandatory | Establish baseline; identify existing prescriptions |
| Every refill/follow-up for Schedule II | Mandatory | High abuse potential; frequent monitoring required |
| Follow-up for Schedule III-V | Recommended | State-specific; check regulations |
| New patient with existing CS Rx | Mandatory | Verify current prescriptions; identify providers |
| Random checks (chronic CS patients) | Best Practice | Quarterly minimum for ongoing monitoring |
| Suspected misuse or diversion | Mandatory | Document investigation and clinical response |
Documentation Template
PDMP Review Template
PDMP REVIEW — [DATE] Prescription drug monitoring program reviewed on [MM/DD/YYYY]. Results: [consistent / inconsistent] with the prescribed medication regimen. [No unexpected controlled substances identified.] OR [Unexpected findings: specify prescriber(s), medications, dates — see clinical response below.] Clinical response to findings: [document action taken]. Next scheduled PDMP review: [date or "at next visit"].
4
UDS Ordering Guidelines
| Indication | Frequency | Notes |
|---|---|---|
| Baseline at intake | Once | All SUD patients; any patient starting CS |
| Random (active SUD) | Monthly minimum | Unannounced; observed collection preferred |
| Random (stable remission) | Quarterly | Continue for first year of stability |
| For-cause testing | As indicated | Suspected relapse, behavioral changes, missed appointments, pill count discrepancies |
| Confirmatory testing | As needed | When immunoassay result is unexpected |
| Extended panels | Clinical judgment | When picture suggests substances not on standard panel |
Order Documentation Template
UDS Order Template
UDS ORDERED — [DATE] Type: [Immunoassay / Confirmatory GC-MS / Extended panel] Indication: [Baseline / Random / For-cause / Confirmatory] For-cause rationale (if applicable): [specify clinical observations] Collection: [Observed / Unobserved] Chain of custody: [Yes / No]
5
UDS Interpretation Guide
Expected vs Unexpected Results Matrix
| Substance | Detection Window | Expected For... | Common False Positives | Action if Unexpected |
|---|---|---|---|---|
| Opioids | 1-3 days | Prescribed opioids | Quinolones, rifampin, poppy seeds | Confirmatory testing |
| Buprenorphine | 3-7 days | Prescribed BUP | None significant | Check bup assay separately |
| Methadone | 3-7 days | Prescribed methadone | Diphenhydramine, quetiapine | Confirm via GC-MS |
| Benzodiazepines | 3-7 days (short), up to 6 weeks (long) | Prescribed benzos | Sertraline, oxaprozin | Confirm then identify specific benzo |
| THC | 3-30 days (use dependent) | State legal use | Hemp CBD products, NSAIDs (rarely) | Clinical discussion |
| Cocaine | 2-4 days | None therapeutic | Nothing significant | Clinical interview |
| Amphetamines | 2-4 days | Prescribed stimulants | Labetalol, pseudoephedrine, trazodone, bupropion, ranitidine | Confirmatory GC-MS |
| PCP | 7-14 days | None therapeutic | Dextromethorphan, venlafaxine, tramadol | Confirmatory testing |
| Alcohol | EtG 80hrs, EtOH 7-12hrs | None therapeutic | Hand sanitizer (EtG), mouthwash | Clinical context |
Detection Window Details
Short-acting opioids: 1-3 days | Heroin (as morphine): 2-3 days | Oxycodone: 2-4 days | Methadone: 3-7 days | Buprenorphine: 3-7 days
Absence of Prescribed Medication
Possible explanations when expected medication is absent:
- Diversion (selling or giving away medication)
- Not taking as prescribed (taking PRN, running out early)
- Recent dose taken before test (urine too dilute)
- Timing of last dose (metabolized before collection)
- Assay sensitivity limitations
Absent Expected Medication Template
ABSENT PRESCRIBED MEDICATION DISCUSSION — [DATE] Expected substance [drug name] was absent on UDS dated [date]. Patient response when asked: [document patient's explanation]. Clinical assessment: [consistent / inconsistent with clinical picture]. Plan: [describe action — pill count, more frequent UDS, medication adjustment, referral, etc.]
6
Documentation Templates
1. Consistent UDS Template
Consistent UDS
UDS RESULTS — [DATE] Urine drug screen performed on [date]. Results: CONSISTENT with prescribed medication regimen. Prescribed medications detected: [list]. No unexpected substances identified. Patient reports appropriate medication adherence. Plan: Continue current treatment; next UDS scheduled [date].
2. Unexpected Substance Found Template
Unexpected Substance
UDS RESULTS — UNEXPECTED FINDING — [DATE] Urine drug screen performed on [date]. Results: UNEXPECTED substance detected: [specify substance and level if quantitative]. Patient response to results: [document discussion]. Clinical assessment: [assess for relapse, false positive, or legitimate explanation]. Confirmatory testing: [ordered / not indicated because...]. Plan: [adjust monitoring frequency / consider level of care change / other interventions]. Follow-up: [specify actions and timeline].
3. Absent Expected Substance Template
Absent Expected Substance
UDS RESULTS — ABSENT EXPECTED MEDICATION — [DATE] Urine drug screen performed on [date]. Results: Prescribed [medication name] NOT DETECTED. Possible explanations discussed with patient: - Taking medication less frequently than prescribed - Recent dose before testing - Diversion Patient explanation: [document]. Clinical assessment: [consistent / inconsistent] with clinical picture. Additional measures: [pill count ordered / observed dosing / more frequent UDS]. Plan: [specific actions].
4. For-Cause UDS Template
For-Cause UDS
FOR-CAUSE UDS ORDERED — [DATE] Indication for for-cause testing: [ ] Suspected relapse [ ] Behavioral changes observed [ ] Missed appointments [ ] Pill count discrepancy [ ] PDMP findings [ ] Other: [specify] Clinical observations prompting test: [detailed description]. Collection: [Observed / Unobserved] Chain of custody: [Yes / No] Results: [pending / specify results]. Plan based on results: [describe].
5. PDMP Consistent Template
PDMP Consistent
PDMP REVIEW — [DATE] PDMP reviewed on [MM/DD/YYYY] at [time]. Results: CONSISTENT with prescribed regimen. No other controlled substance prescriptions identified. No concerning patterns detected. Next PDMP review: [at next visit / specify date].
6. PDMP Unexpected Findings Template
PDMP Unexpected Findings
PDMP REVIEW — UNEXPECTED FINDINGS — [DATE] PDMP reviewed on [MM/DD/YYYY] at [time]. Unexpected findings: - Other prescriber(s): [name, DEA#, specialty] - Medication(s): [list] - Date(s): [list] - Quantity/Supply: [specify if concerning] Patient discussion: - Patient [was / was not] aware of other prescriptions - Explanation provided: [document] - Clinical assessment: [consistent / inconsistent] Action taken: [ ] Contacted other prescriber: [name, date] [ ] Revised treatment plan [ ] Increased monitoring [ ] Considered taper/discontinuation [ ] Other: [specify] Follow-up plan: [describe].
7. Combined PDMP+UDS Normal Visit Template
Combined Normal Visit
CONTROLLED SUBSTANCE MONITORING — [DATE] PDMP Review: Reviewed on [date]. Results consistent with prescribed regimen. No unexpected prescribers or medications. UDS Results: [Date performed] — Results consistent with prescribed medications. No unexpected substances. Patient Assessment: [stable / requires adjustment]. Patient reports [adherence level]. Pill Count: [appropriate / discrepancy noted: describe]. Plan: Continue [medication] [dose]. Next monitoring: [schedule].
8. High-Risk Documentation Template
High-Risk Patient
HIGH-RISK CONTROLLED SUBSTANCE MONITORING — [DATE] Risk Level: HIGH (ORT score: [X], clinical factors: [list]) Current CS Agreement: Signed [date], reviewed today. Monitoring Protocol: - Visit frequency: Every [X] weeks - UDS frequency: Random, monthly minimum - PDMP checks: Every visit - Pill counts: [random / scheduled] Today's findings: - PDMP: [results] - UDS: [results / date ordered] - Clinical stability: [assessment] Risk mitigation: [ ] Discussed diversion risks [ ] Reinforced agreement terms [ ] Assessed for SUD treatment needs [ ] Considered MAT referral Plan: Continue current protocol / [modifications].
7
Controlled Substance Agreement Template
Full CSA Template
CONTROLLED SUBSTANCE AGREEMENT Patient Name: _________________________ Date: _______________ I understand that [provider name] has prescribed [medication names] for the treatment of [condition]. I agree to the following: 1. MEDICATION USE - I will take medications exactly as prescribed - I will not increase dose or frequency without provider approval - I will not share, sell, or give away my medications - I will safeguard medications from loss or theft 2. SINGLE PRESCRIBER - I will obtain controlled substances ONLY from [provider/practice name] - I will notify this office of any emergency prescriptions from other providers 3. SINGLE PHARMACY - I will fill prescriptions at: [pharmacy name/address] - Changes require advance approval 4. APPOINTMENTS - I will keep all scheduled appointments - I will provide [X] hours notice for cancellations - Lost/stolen medication will NOT be replaced early 5. URINE DRUG TESTING - I consent to random urine drug screens - Refusal may result in discontinuation of controlled substances - I understand observed collection may be required 6. PDMP MONITORING - I consent to PDMP queries by this practice - I authorize communication with other prescribers 7. CONSEQUENCES Violations of this agreement may result in: - Taper and discontinuation of controlled substances - Referral to substance use disorder treatment - Notification of appropriate authorities if diversion suspected Patient Signature: _________________________ Date: ___________ Provider Signature: _______________________ Date: ___________
8
Risk Stratification
Risk Assessment Tools
- ORT (Opioid Risk Tool): 5-item questionnaire assessing risk factors for opioid misuse
- DIRE Score: Assesses suitability for long-term opioid therapy
- SOAPP-R: Screens for risk of aberrant medication-related behavior
| Risk Level | Features | Monitoring Frequency | Documentation Requirements |
|---|---|---|---|
| Low (ORT 0-3) | No personal/family SUD history, no psychiatric comorbidity | Standard (PDMP at visits, UDS baseline) | Standard documentation |
| Moderate (ORT 4-7) | Some risk factors, stable psychiatric condition | Increased (PDMP every visit, UDS random quarterly) | CS agreement, risk discussion documented |
| High (ORT ≥8) | Active SUD, diversion history, unstable psychiatric condition | Intensive (PDMP every visit, UDS monthly, pill counts) | Full high-risk protocol, addiction specialist involvement |
9
DEA Compliance
DEA Registration
- DEA Form 224: Required for prescribing controlled substances
- Registration must be current and displayed at practice location
- Separate registration required for each state of practice
- Must register with state PDMP where available
Schedule-Specific Rules
Schedule II Prescribing Rules
No refills permitted. New prescription required for each fill. Quantity limits apply. Emergency supply limited to immediate need period.
Schedule III-V Prescribing Rules
Maximum 5 refills within 6 months from issue date. Partial fills permitted with specific documentation.
Electronic Prescribing (EPCS)
- Federal mandate for Schedule II prescriptions (most states)
- Two-factor authentication required
- Audit trail of all prescribing activity
- State-specific variations may apply
Documentation Requirements
- DEA number on all controlled substance prescriptions
- Patient address on all prescriptions
- Prescriber's NPI number
- Diagnosis/indication for Schedule II (state-specific)
10
Clinical Pearls
1
Document the Act, Not Just the Result
Record "PDMP reviewed on [date]" even when results are normal. The absence of documentation is the absence of the act in legal proceedings.
2
Time-Stamp Everything
Note the exact date and time of PDMP review. Screenshots with timestamps provide the strongest documentation.
3
False Positives Are Common
Antidepressants, antihistamines, and even foods can trigger false positives. Always confirm unexpected results before clinical action.
4
Negative UDS ≠ Non-Adherence
Absence of prescribed medication may indicate recent dosing, dilute urine, or assay limitations—not necessarily diversion.
5
Observed Collection is Gold Standard
When diversion is suspected, observed collection eliminates substitution concerns. Document why observed collection was indicated.
6
Chain of Custody Matters
For any result that may have legal implications, maintain strict chain of custody. Document who collected, when, and handling procedures.
7
Communicate with Other Prescribers
When PDMP reveals unexpected prescribers, contact them. Document the conversation—it may reveal legitimate care coordination.
8
Know Your State's PDMP Requirements
Requirements vary significantly. Some states mandate checks for every CS prescription; others only for Schedule II. Stay current.
9
Taper Documentation is Critical
When discontinuing controlled substances due to misuse, document the rationale thoroughly. This protects against abandonment claims.
10
Trust But Verify
Patients with legitimate pain or ADHD can still develop problematic use patterns. Objective monitoring supports the therapeutic relationship.